Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company ...

Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company’s launch of FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous ...

Abeona Therapeutics Inc.: Abeona Therapeutics Provides Business Update Highlighting Building Momentum in ZEVASKYN Commercial Launch

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company's launch of FDA-approved ZEVASKYN (prademagene ...

Sangamo Therapeutics, Inc.: Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally ...